S2-E61.3 – Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?
We discuss how weight loss and GLP-1s or Double/Triple Agonists in relation to SPLENDOR.
December 19, 2021
We discuss how weight loss and GLP-1s or Double/Triple Agonists in relation to SPLENDOR.
SPLENDOR lead author Ali Amirian Shares Novel Insights About the Impact of Bariatric Surgery on MACE and MALO
Lead Author Ali Aminian shares key findings from the SPLENDOR study.
Learn about the non-invasive sessions, including fireside chats, and discussion of novel targets at NASH-TAG 2022
Learn about the consortium updates and artificial intelligence content at NASH-TAG 2022
Learn about the drug development content at NASH-TAG 2022
The Surfers and guest Jörn Schattenberg review NASH-TAG 2022, a unique event and the first meeting on the 2022 NAFLD and NASH calendar.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” This conversation focuses on the question “What’s Next,” which makes the scale of the challenge clear and compelling.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”